CD133 receptor mediated delivery of STAT3 inhibitor for simultaneous elimination of cancer cells and cancer stem cells in oral squamous cell carcinoma

Med Hypotheses. 2019 Aug:129:109241. doi: 10.1016/j.mehy.2019.109241. Epub 2019 May 20.

Abstract

Oral Squamous Cell Carcinoma (OSCC) is one of the major causes of cancer related deaths worldwide. Presence of chemoresistant cancer stem cells is the major reason behind metastasis, tumor relapse and treatment resistance in OSCC. STAT 3 signalling plays a key role in survival of cancer stem cells (CSC's), Epithelial Mesenchymal Transition (EMT) mediated metastasis in OSCC. CD 133 is the surface marker for identification of cancer stem cells. In the present study we hypothesise the selective targeting of CSC's using CD 133 mediated delivery of STAT 3 inhibitor, Niclosamide to specifically target CSC's and Non CSC's.

Keywords: CD 133; Cancer stem cells; Epithelial mesenchymal transition; Metastasis; Niclosamide; Oral squamous cell carcinoma; STAT 3.

Publication types

  • Letter

MeSH terms

  • AC133 Antigen / chemistry*
  • Apoptosis
  • Carcinoma, Squamous Cell / drug therapy*
  • Drug Carriers
  • Drug Delivery Systems*
  • Epithelial-Mesenchymal Transition
  • Humans
  • Models, Theoretical
  • Mouth Neoplasms / drug therapy*
  • Neoplasm Recurrence, Local
  • Neoplastic Stem Cells / drug effects*
  • Niclosamide / administration & dosage*
  • STAT3 Transcription Factor / antagonists & inhibitors*
  • Signal Transduction

Substances

  • AC133 Antigen
  • Drug Carriers
  • PROM1 protein, human
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Niclosamide